Our study shows how clinicians can reduce risk and increase effectiveness for oxycodone dosing by ( 1 ) determining the patient 's likely metabolic response through testing a patient 's CYP2D6 phenotype , and ( 2 ) calculating clinical pharmacokinetics specific to the patient 's CYP2D6 phenotype to design a personalized oxycodone dosing regimen .